Frequently Asked Questions
The global respiratory inhaler devices market was valued at USD 35.2 Billion in 2022.
The respiratory inhaler devices market is expected to grow at a CAGR of 5.20% between 2023 and 2030, reaching USD 50.19 Billion in 2030.
Metered dose inhalers are the leading segment by product type, holding around half of the share in value in 2022.
The adult patient governs the highest share of the patient segment in respiratory inhaler devices worldwide
The asthma segment will post the highest CAGR during the forecast period.
North America is fuelling the growth of the respiratory inhaler devices industry, with a nearly two-fifth share in 2022.
The top players include Adherium, AstraZeneca, Boehringer Ingelheim International GmbH, CHIESI Farmaceutici S.p.A., GlaxoSmithKline plc, Propeller Health, Teva Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Ltd., 3M, Cipla Inc., Koninklijke Philips N.V., Merck & Co., Inc., Omron Healthcare, Inc., Cohero Health, Inc., PARI GmbH, Glenmark Pharmaceuticals Limited, Senzer Ltd, Novartis AG, HELTMAN Medikal A.S., and Mundipharma International and others
The rise in the per capita income of people worldwide is the major market driver.
Increasing adoption of alternative therapies such as oral medication or subcutaneous injections is the major factor restraining the growth of the respiratory inhaler devices industry.
the increasing adoption of combination therapies for asthma is an opportunity for the respiratory inhaler devices industry.